Evox populates its pipeline

As Evox Therapeutics Ltd. continues to refine the platform with which it develops exosome-based therapeutics, the company plans to use its £35.5 million ($45.9 million) series B round to start clinical trials on as many as three rare disease therapies in its pipeline.

Oxford, U.K.-based Evox is developing exosome therapies that use specially engineered versions of the extracellular vesicles to ferry therapeutic cargoes to specific tissues, cell types or other areas of interest that are otherwise difficult to reach with drugs. The payloads can include proteins, nucleic acids, antibodies or small molecules...